Median age, years (range) |
16.5 (5–51) |
Male, N (%) |
127 (62%) |
Caucasian/Hispanic/Black/Asian/other (N) |
149/32/14/6/3 |
Disease status at study entry
|
|
No active disease after surgery, N (%) |
57 (29%) |
Active disease after surgery, N (%) |
143 (72%) |
Local Relapse, N (%) |
9 (6%) |
Metastatic, N (%) |
132 (64%) |
Pulmonary |
107 (52%) |
Bone |
9 (4%) |
Other |
21 (10%) |
Indicator lesions, N (%) |
79 (39%) |
Lesion site, N (%) |
|
Primary tumor |
14 (8) |
Lung metastases |
72 (35%) |
Other (e.g. bone or soft tissue metastases) |
11 (5%) |
Median time from initial osteosarcoma diagnosis to first mifamurtide dose, months (range) |
24 (1–136) |